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Abstract
Introduction: This study is aimed at determining the incidence, survival rate, life expectancy, quality-adjusted life
expectancy (QALE) and prognostic factors in patients with cancer in different organ systems undergoing prolonged
mechanical ventilation (PMV).
Methods: We used data from the National Health Insurance Research Database of Taiwan from 1998 to 2007 and
linked it with the National Mortality Registry to ascertain mortality. Subjects who received PMV, defined as having
undergone mechanical ventilation continuously for longer than 21 days, were enrolled. The incidence of cancer
patients requiring PMV was calculated, with the exception of patients with multiple cancers. The life expectancies
and QALE of patients with different types of cancer were estimated. Quality-of-life data were taken from a sample
of 142 patients who received PMV. A multivariable proportional hazards model was constructed to assess the effect
of different prognostic factors, including age, gender, type of cancer, metastasis, comorbidities and hospital levels.
Results: Among 9,011 cancer patients receiving mechanical ventilation for more than 7 days, 5,138 undergoing
PMV had a median survival of 1.37 months (interquartile range [IQR], 0.50 to 4.57) and a 1-yr survival rate of 14.3%
(95% confidence interval [CI], 13.3% to 15.3%). The incidence of PMV was 10.4 per 100 ICU admissions. Head and
neck cancer patients seemed to survive the longest. The overall life expectancy was 1.21 years, with estimated
QALE ranging from 0.17 to 0.37 quality-adjusted life years for patients with poor and partial cognition, respectively.
Cancer of liver (hazard ratio [HR], 1.55; 95% CI, 1.34 to 1.78), lung (HR, 1.45; 95% CI, 1.30 to 1.41) and metastasis (HR,
1.53; 95% CI, 1.42 to 1.65) were found to predict shorter survival independently.
Conclusions: Cancer patients requiring PMV had poor long-term outcomes. Palliative care should be considered
early in these patients, especially when metastasis has occurred.
Introduction
The number of cancer patients has been steadily increas-
ing, and cancer has become the leading cause of death in
many countries [1,2]. Patients with malignancies are at
risk of developing acute respiratory failure due to the
underlying cancer as well as to its treatment, and many of
these patients will need mechanical ventilation support
while in the ICU. In hospitalized patients with solid
tumors, approximately 1% have been diagnosed with acute
respiratory failure [3]. The incidence varies from 9% to
almost half of the population in patients with hematologic
malignancies [3,4]. Studies of patients with cancer
admitted to ICUs have demonstrated that mechanical ven-
tilation has been provided for 42% to 83% of these patients
[3,5-9].
The number of patients requiring prolonged mechanical
ventilation (PMV), defined as having undergone mechani-
cal ventilation continuously for longer than 21 days, is
rapidly increasing because of the advances in intensive
care [10]. During 2009, approximately 30,000 patients
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required PMV as recorded by the National Health Insur-
ance (NHI) of Taiwan, which accounted for 4.76% of total
NHI healthcare expenditures. This financial burden has
now become one of the major threats to the sustainability
of the NHI [11,12]. In our previous study, cancer patients
requiring PMV account for up to 10.6% of all PMV
patients [13]. Although the NHI reimburses all the direct
healthcare expenditures of these patients, there is still out-
of-pocket money spent for indirect care by the patients’
families that results in a financial burden [14]. Moreover,
withdrawal of mechanical ventilation was not legally
allowed in Taiwan before 2011. Thus, it would help
patients and their families to know which patients are
least likely to survive on a long-term basis so that further
invasive interventions could be reconsidered.
Therefore, accurate prognoses are essential to propose
and establish a sustainable national policy and to facilitate
communication among different stakeholders. There is
limited information on lifetime outcomes in cancer
patients who have required PMV. The aims of this study
were to determine the incidence and life expectancy of
cancer patients requiring PMV and to identify factors
associated with lifetime survival, as well as the quality-
adjusted life expectancy (QALE) of cancer patients under-
going PMV.
Materials and methods
Study population and data sets
The current study was approved by the Institutional
Review Board of National Taiwan University Hospital (IRB
200912072R). We retrieved the data from the National
Health Insurance Research Database (NHIRD), a reimbur-
sement data file that we obtained from the NHI of Taiwan.
It was transformed into a research database by the
National Health Research Institutes (Chunan, Taiwan).
The identification numbers of all individuals in the reim-
bursement data file were encrypted to protect the patients’
privacy. These files contained detailed demographic data
(including birthdate and gender) and information regard-
ing the healthcare services provided for each patient,
including all payments for outpatient visits, hospitaliza-
tions, prescriptions and intervention procedures. In addi-
tion, up to five diagnoses were provided for the
hospitalization. In total, 8,906,406 individuals had under-
gone invasive or noninvasive respiratory care at least once
during the period from 1997 to 2007. This number corre-
sponds to approximately 29.4% of the entire insured popu-
lation. Because the government has established guidelines
stating that no more than 10% of all data can be drawn for
research, we applied for a random sample of these patients
with a 3.4:1 sampling ratio. Namely, 1 record of a patient
who had undergone respiratory care was randomly drawn
from every 3.4 records so that the total data would be
close to the 10% limit. Subjects who were over the age of
17 years and had undergone extended mechanical ventila-
tion for longer than 7 days were enrolled, wherein PMV
was defined as patients requiring more than 21 days of
mechanical ventilation [15,16]. To ensure that all of the
patients were incident cases, we excluded all prevalent
cases found in 1997 and began the collection in 1998. To
select cancer patients, we linked our data set with the reg-
istry of cancer under NHIRD catastrophic illness and
excluded cases with multiple cancer diagnoses, as sum-
marized in Figure 1. The incidences were the risks of
PMV among different types of cancer patients admitted to
the ICU during a period from 1998 to 2007.
Statistical analysis
Determinants or prognostic factors of survival
Age, gender, hospital level and comorbidities were
included as the major determinants with which to explore
the survival of these patients. Differences in survival were
examined across gender and four categories of age
(younger than 65, 65 to 74, 75 to 84, and 85 years and
older). The hospital level was retrieved from the NHI
claim codes and was classified into district hospital
(usually fewer than 250 beds), regional hospital (usually
250 to 1,000 beds) or medical center (usually more than
1,000 beds). The data for each inpatient hospitalization
included up to five diagnoses, which were coded according
to the International Classification of Diseases, Ninth Revi-
sion, Clinical Modification. The diagnoses were reclassified
into 260 categories according to the Clinical Classifications
Software (CCS) for ICD-9-CM [17]. The classification of
cancer types and metastatic status in our study were sim-
plified from the multilevel CCS codes to collect sufficient
numbers of subcohorts. Comorbidities were identified
from the single-level CCS and reclassified into 40 broad
categories excluding cancer. Comorbidities occurring in
less than 5% of the PMV study population were excluded.
Univariate Cox regression analysis was used first to exam-
ine the correlation between each prognostic variable and
the length of survival. Spearman’s rank correlation was
calculated to explore any collinearity between the studied
variables. Multivariable Cox regression analyses were per-
formed to determine the prognostic impact of cancer
types after adjusting for potential confounding variables.
Variables considered in the models included gender, four
categories of age, period of receiving PMV treatment
(1998 to 2000, 2001 to 2004 and 2005 to 2007), extent of
cancer (local vs metastasis), cancer types (organ system or
location), acute comorbidities, concurrent organ disorder
(chronic comorbidities) and hospital level (district hospital,
regional hospital or medical center). Stepwise selection
processes were applied to select the comorbidities of prog-
nostic relevance. Acute and chronic comorbidities were
Shih et al. Critical Care 2013, 17:R144
http://ccforum.com/content/17/4/R144
Page 2 of 10
considered both separately and concurrently in the Cox
regression models. All statistical analyses were performed
by using SAS version 9.1 software (SAS Institute, Cary,
NC, USA).
Survival analysis and estimation of life expectancy
Each new patient who fulfilled the definition of mechanical
ventilation was followed from the seventh day of mechani-
cal ventilation until he or she died or was censored on 31
December, 2007. The median survival and long-term sur-
vival rates were estimated using the Kaplan-Meier method.
Patients who survived more than 21 days were followed
under an integrated system of reduced intensive respira-
tory care [18]. Their lifetime survival was estimated up to
300 months using a linear extrapolation of a logit-trans-
formed curve for the survival ratio between the PMV and
an age- and gender-matched reference population gener-
ated by the Monte Carlo method from the life table of the
general population of Taiwan (Figure 2). The detailed
method and mathematical proof assuming a constant
excess hazard were described in our previous reports
[19-21]. To facilitate computation, we used iSQoL, a soft-
ware program that was built on the R programming lan-
guage for lifetime expectancy estimation and 300-month
extrapolation that can be downloaded for free from the
website [22].
Estimation of quality-adjusted life expectancy
The lifetime survival probabilities along the duration to
dates (or time after PMV onset) were multiplied (or
adjusted) with the quality-of-life (QoL) values to obtain a
quality-adjusted survival curve. The sum of the total area
under this curve was the QALE with quality-adjusted life
years (QALYs) as the common unit [23]. Our QoL data
were taken from a sample of 142 patients under PMV and
measured using the EQ-5D Health Questionnaire and were
classified into either partial or poor cognition [24,25]. Partial
cognition was defined as an Mini Mental State Examination
score higher than 15. Poor cognition was categorized
as scores equal to or less than 15. The detailed estimation
method was summarized and reported in a previous article
evaluating the cost-effectiveness of PMV treatment [14].
Figure 1 Flow diagram of selection process used for the study cohort.
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Results
Patient characteristics
A total of 9,011 cancer patients under extended mechani-
cal ventilation were included during the study period. The
median survival was generally less than 2 months, and the
1-yr survival rate was mostly less than 20%. Among those
patients studied, 5,138 had undergone mechanical ventila-
tion for more than 21 days. Their mean age was 69.1 years
(SD ± 13.8), and 33% were females. The median survival
was 1.37 months (interquartile range [IQR], 0.50 to 4.57)
(Table 1), which is slightly longer than the 1.13 months
(IQR, 0.47 to 4.30) of the 240 excluded cases with multiple
cancers. About one-third of the cases were patients with
cancers occurring in the head and neck or in the respira-
tory tract. About one-fourth were metastasized cancers,
indicating that advanced cancer patients treated with
PMV were not uncommon. The most frequently encoun-
tered acute comorbidities were septicemia (22.4%),
followed by gastrointestinal hemorrhage (10.9%) and
shock (10.6%).
Figure 2 Survival analysis and estimation of life expectancy. (A) Estimated survival curve for patients with head and neck cancer
undergoing prolonged mechanical ventilation (indicated by dashed line) and age- and gender-matched referents generated by Monte Carlo
method based on life tables of vital statistics of Taiwan. (B) Plot of logit-transformed curve of the survival ratio between index and referents
populations showing the fulfillment of constant excess hazard.
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Table 1 Characteristics and survival of cancer patients categorized by duration of mechanical ventilation
(1998 to 2007).a
Duration of mechanical ventilation
>7 days (extended MV) >21 days (prolonged MV)











Total 9,011 1.54 (0.67 to 5.90) 17.6 (16.8 to 18.4) 5138 1.37 (0.50 to 4.57) 14.3 (13.3 to 15.3) 1.21 (0.10)
Gender and age (yr)
Male
17 to 64 2,282 1.64 (0.66 to 8.29) 20.4 (18.8 to 22.2) 1,010 1.17 (0.43 to 3.73) 13.9 (11.8 to 16.2) 1.52 (0.22)
65 to 74 1,686 1.50 (0.67 to 5.10) 16.7 (14.9 to 18.5) 986 1.37 (0.50 to 4.23) 12.8 (10.8 to 15.1) 1.02 (0.13)
75 to 84 1,729 1.50 (0.70 to 4.94) 15.1 (13.4 to 16.9) 1,116 1.40 (0.53 to 4.63) 13.3 (11.3 to 15.4) 0.86 (0.09)
85 or older 425 1.64 (0.77 to 4.50) 14.9 (11.6 to 18.6) 318 1.80 (0.63 to 4.73) 16.4 (12.4 to 20.9) 0.95 (0.19)
Female
17 to 64 1,129 1.40 (0.60 to 6.84) 19.8 (17.5 to 22.3) 573 1.30 (0.43 to 5.43) 17.2 (14.2 to 20.5) 1.49 (0.31)
65 to 74 788 1.54 (0.64 to 5.27) 17.2 (14.6 to 20.0) 459 1.40 (0.63 to 4.53) 13.9 (10.9 to 17.3) 1.03 (0.24)
75 to 84 727 1.50 (0.67 to 5.50) 14.3 (11.8 to 17.1) 499 1.47 (0.57 to 5.83) 14.8 (11.7 to 18.2) 1.07 (0.30)
85 or older 234 1.84 (0.86 to 6.67) 17.6 (12.9 to 23.0) 177 1.70 (0.73 to 6.20) 16.4 (11.1 to 22.6) 0.82 (0.24)
Extent of cancer
Local 5,954 1.87 (0.79 to 8.32) 20.6 (19.5 to 21.7) 3,900 1.60 (0.57 to 5.97) 16.9 (15.7 to 18.2) 1.36 (0.11)
Metastasis 3,057 1.07 (0.50 to 3.12) 11.7 (10.6 to 12.9) 1,238 0.93 (0.37 to 2.10) 5.9 (4.6 to 7.3) 0.64 (0.15)
Cancer type
Head and neck 1,432 2.60 (0.89 to 13.32) 26.0 (23.7 to 28.3) 705 1.77 (0.70 to 7.57) 20.0 (17.0 to 23.1) 1.57 (0.45)
Bone and connective
tissue
52 1.37 (0.77 to 2.74) 10.0 (3.7 to 20.1) 38 0.87 (0.37 to 1.77) 2.8 (2.1 to 12.2) -b
Liver 775 0.87 (0.40 to 2.50) 10.5 (8.4 to 12.8) 297 1.00 (0.40 to 2.43) 6.8 (4.2 to 10.2) 0.45 (0.19)
Lung 1,752 1.10 (0.56 to 2.93) 10.5 (9.1 to 12.1) 965 1.00 (0.37 to 2.57) 6.6 (5.1 to 8.3) 0.77 (0.13)
Esophagus 495 2.07 (0.86 to 9.17) 22.5 (18.8 to 26.3) 232 1.03 (0.47 to 2.83) 10.2 (6.6 to 14.6) 0.98 (0.33)
Lymphatic and
hematopoietic tissue
578 1.20 (0.57 to 4.47) 14.2 (11.5 to 17.2) 289 1.27 (0.43 to 4.33) 14.3 (10.4 to 18.7) 1.12 (0.36)
Urinary organs 420 1.74 (0.90 to 4.94) 16.0 (12.6 to 19.8) 306 1.30 (0.60 to 3.87) 12.8 (9.2 to 16.9) 0.88 (0.22)
Female genital 345 1.37 (0.67 to 5.37) 17.2 (13.4 to 21.5) 214 1.23 (0.50 to 5.23) 14.1 (9.8 to 19.3) 0.98 (0.63)
Pancreas and other GI
organs
176 1.27 (0.61 to 3.57) 13.2 (8.6 to 18.7) 99 1.33 (0.43 to 4.90) 15.1 (8.9 to 22.9) -b
Stomach 503 1.57 (0.74 to 5.44) 17.7 (14.4 to 21.3) 305 1.60 (0.60 to 5.60) 17.0 (12.9 to 21.6) 0.98 (0.38)
Thyroid 77 1.81 (0.87 to 10.34) 24.9 (15.7 to 35.2) 56 1.27 (0.50 to 5.17) 18.6 (9.5 to 30.0) -b
Breast 375 1.40 (0.57 to 4.97) 17.1 (13.3 to 21.3) 223 1.40 (0.60 to 6.47) 18.9 (13.8 to 24.6) 1.17 (0.48)
Skin 100 2.30 (0.97 to 9.10) 21.3 (13.7 to 30.0) 83 1.83 (0.60 to 6.33) 18.1 (10.6 to 27.3) -b
Brain and nervous
system
280 2.40 (1.17 to 7.60) 18.0 (13.5 to 23.0) 228 1.97 (0.83 to 7.13) 15.8 (11.2 to 21.2) 1.18 (0.50)
Colorectal 1,019 1.91 (0.80 to 9.60) 22.8 (20.2 to 25.5) 650 1.77 (0.60 to 7.07) 18.8 (15.8 to 22.0) 1.47 (0.23)
Male genital 435 1.81 (0.77 to 7.14) 18.6 (14.9 to 22.5) 303 2.17 (0.70 to 9.20) 19.9 (15.4 to 24.8) 1.15 (0.41)
Others 197 1.47 (0.77 to 7.30) 20.8 (15.3 to 26.7) 145 1.03 (0.40 to 3.70) 14.9 (9.5 to 21.3) -b
Acute comorbidities
Acute renal failure 630 0.90 (0.50 to 1.80) 7.4 (5.4 to 9.8) 359 0.90 (0.37 to 1.93) 8.4 (5.6 to 11.9) 0.44 (0.20)
Septicemia 2,013 1.02 (0.56 to 2.40) 9.8 (8.5 to 11.2) 1,155 0.93 (0.37 to 2.60) 10.2 (8.5 to 12.2) 0.94 (0.24)
Shock 1,038 0.89 (0.44 to 2.07) 9.0 (7.3 to 10.8) 547 0.87 (0.33 to 2.40) 9.4 (7.0 to 12.1) 0.96 (0.20)
GI hemorrhage 941 1.40 (0.60 to 4.70) 15.0 (12.8 to 17.4) 559 1.20 (0.40 to 4.27) 14.2 (11.4 to 17.3) 1.12 (0.26)
Other injury and
poisoning
729 2.90 (1.00 to 16.57) 28.4 (25.1 to 31.8) 392 2.07 (0.77 to 8.50) 21.8 (17.7 to 26.1) 1.61 (0.45)
Cerebrovascular disease 592 2.37 (0.89 to 12.14) 25.2 (21.7 to 28.9) 426 2.67 (0.83 to 12.23) 25.0 (20.8 to 29.4) 1.61 (0.38)
Concurrent organ disorder
(chronic comorbidities)
Hypertension 615 2.60 (0.89 to 16.04) 27.3 (23.7 to 31.0) 354 2.20 (0.80 to 8.90) 21.7 (17.3 to 26.4) 1.83 (0.44)
COPD 615 2.10 (0.87 to 9.97) 23.0 (19.6 to 26.4) 428 2.00 (0.67 to 8.73) 20.6 (16.8 to 24.6) 1.34 (0.38)
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Incidence of prolonged mechanical ventilation
The overall incidence of cancer patients requiring PMV
was 10.4 per 100 ICU admissions. The incidences of
PMV in different types of cancer are summarized in
Table 2. Lung cancer patients yielded the highest inci-
dence of PMV (14.9 per 100 ICU admissions). Patients
with liver cancer exhibited the lowest incidence of PMV
(4.3 per 100 ICU admissions).
Survival rate, life expectancy and quality-adjusted life
expectancy
The results of survival rate, life expectancy and QALE of
the study populations categorized using different variables
are summarized in Tables 1 and 2. Patients with metastatic
cancer status have a generally poor prognosis, with a 1-yr
survival rate of 5.9% (95% confidence interval [CI], 4.6% to
7.3%) and estimated life expectancy of 0.64 year. In addi-
tion, the life expectancies and QALEs are generally better
in patients with head and neck or colorectal cancer. Those
patients with liver or lung cancer had a poor prognosis.
Prognostic factors
The results of three multivariate Cox regression models
are summarized in Table 3. Male gender, metastatic can-
cer and comorbidities of acute renal failure, shock, septi-
cemia and gastrointestinal hemorrhage significantly
predicted shorter survival after controlling for other risk
factors. Patients treated in medical centers seem to have
a slightly better prognosis after adjustment for other pre-
dictors (Table 3). In addition, age and period of receiving
PMV treatment had no significant prognostic impact on
survival for cancer patients.
Discussion
Although there are studies reporting the poor prognosis
of patients with advanced cancer hospitalized in the ICU
Table 2 Incidence and the estimated quality-adjusted life expectancy for cancer patients undergone prolonged
mechanical ventilationa
Type of cancer Number of ICU admissions Incidence of PMV per 100 ICU
admissions (95% CI)





Lung 6,114 14.9 (8.4 to 23.5) 0.23 (0.06) 0.11 (0.03)
Others 608 14.3 (8.4 to 23.5) -b -b
Male genital 2,197 14.2 (8.4 to 23.5) 0.33 (0.14) 0.15 (0.06)
Brain & nervous system 1,490 14.0 (7.7 to 24.5) 0.35 (0.19) 0.16 (0.08)
Lymphatic and
hematopoietic tissue
2,242 13.3 (7.7 to 22.2) 0.35 (0.16) 0.16 (0.06)
Esophagus 1,781 13.0 (6.9 to 22.2) 0.30 (0.13) 0.14 (0.07)
Skin 579 13.1 (7.7 to 22.2) -b -b
Thyroid 432 12.3 (6.9 to 21.0) -b -b
Stomach 2,647 11.1 (6.2 to 19.7) 0.28 (0.13) 0.13 (0.04)
Colorectal 6,213 10.6 (5.5 to 18.4) 0.45 (0.11) 0.20 (0.06)
Urinary organs 2,883 10.4 (5.5 to 18.4) 0.26 (0.08) 0.12 (0.04)
Bone and connective tissue 339 10.3 (5.5 to 18.4) -b -b
Breast 2,072 9.9 (4.8 to 17.1) 0.34 (0.17) 0.16 (0.06)
Head and neck 7,074 8.8 (4.1 to 15.8) 0.48 (0.21) 0.22 (0.08)
Female genital 2,342 8.5 (4.1 to 15.8) 0.28 (0.23) 0.12 (0.11)
Pancreas and other GI
organs
1,097 8.0 (3.5 to 15.8) -b -b
Liver 6,625 4.3 (1.6 to 10.2) 0.12 (0.07) 0.06 (0.02)
aCI, confidence interval; GI, gastrointestinal; ICU, intensive care unit; QALY, quality-adjusted life year; SE, standard error of the mean. bQALE could not be
calculated because of violation of assumption or small numbers.
Table 1 Characteristics and survival of cancer patients categorized by duration of mechanical ventilation
(1998 to 2007).a (Continued)
Hospital level
District 977 1.40 (0.63 to 4.04) 12.6 (10.5 to 14.8) 694 1.40 (0.57 to 5.03) 14.3 (11.7 to 17.1) 1.17 (0.31)
Regional 3,058 1.44 (0.64 to 4.57) 14.4 (13.2 to 15.8) 1,772 1.27 (0.50 to 3.87) 12.2 (10.7 to 13.8) 1.04 (0.22)
Medical center 4,976 1.67 (0.70 to 8.02) 20.5 (19.3 to 21.6) 2,672 1.40 (0.53 to 5.07) 15.6 (14.2 to 17.1) 1.37 (0.18)
aCI, confidence interval; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; IQR, interquartile range; MV, mechanical ventilation; SE, standard error
of the mean. bLife expectancy could not be calculated because of violation of the assumption of constant excess hazard or small numbers.
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and under mechanical ventilation, to the best of our
knowledge, our study is the first to provide the crucial
estimates of survival rates, life expectancies and QALE in
these patients categorized by metastatic status and types
of cancer based on a national database, as summarized in
Tables 1 and 2. We found the median survival of cancer
patients under more than 7 days of mechanical ventila-
tion is generally less than 2 months, with the exception
Table 3 Independent risk factors for mortality in cancer patients undergone prolonged mechanical ventilationa
Variables Risk of death
Crude HR (95% CI) Adjusted HRb(95% CI)
Gender
Female 1.00 1.00
Male 1.07 (1.01 to 1.14) 1.12 (1.04 to 1.20)
Age (yr)
17 to 64 1.00 1.00
65 to 74 0.99 (0.92 to 1.07) 0.99 (0.91 to 1.07)
75 to 84 0.96 (0.89 to 1.03) 1.02 (0.94 to 1.10)
85 or older 0.90 (0.81 to 1.01) 0.98 (0.87 to 1.10)
Extent of cancer
Local 1.00 1.00
Metastatic 1.56 (1.45 to 1.66) 1.53 (1.42 to 1.65)
Cancer type
Head and neck 1.00 1.00
Bone and connective tissue 2.08 (1.49 to 2.90) 2.06 (1.48 to 2.88)
Liver 1.65 (1.43 to 1.90) 1.55 (1.34 to 1.78)
Lung 1.58 (1.42 to 1.75) 1.45 (1.30 to 1.61)
Esophagus 1.44 (1.23 to 1.69) 1.32 (1.13 to 1.54)
Lymphatic and hematopoietic tissue 1.26 (1.09 to 1.45) 1.32 (1.14 to 1.52)
Urinary organs 1.23 (1.07 to 1.43) 1.24 (1.07 to 1.43)
Female genital 1.19 (1.01 to 1.40) 1.23 (1.03 to 1.46)
Pancreas and other GI organs 1.19 (0.96 to 1.48) 1.17 (0.94 to 1.47)
Thyroid 1.14 (0.86 to 1.52) 1.17 (0.88 to 1.56)
Breast 1.10 (0.94 to 1.29) 1.14 (0.96 to 1.35)
Skin 1.07 (0.84 to 1.36) 1.08 (0.84 to 1.38)
Stomach 1.09 (0.9 to 1.26) 1.08 (0.93 to 1.25)
Brain and nervous system 1.01 (0.8 to 1.19) 1.04 (0.89 to 1.22)
Colorectal 1.05 (0.93 to 1.17) 1.04 (0.92 to 1.17)
Male genital 0.95 (0.82 to 1.10) 0.93 (0.80 to 1.09)
Others 1.28 (1.06 to 1.54) 1.14 (0.95 to 1.39)
Acute comorbiditiesc
Acute renal failure 1.43 (1.28 to 1.60) 1.46(1.30 to 1.64)
Septicemia 1.33 (1.24 to 1.43) 1.24(1.15 to 1.34)
Shock 1.32 (1.21 to 1.45) 1.22(1.10 to 1.34)
GI hemorrhage 1.07 (0.98 to 1.18) 1.10(1.01 to 1.21)
Other injury and poisoning 0.78 (0.70 to 0.87) 0.83 (0.74 to 0.92)
Cerebrovascular disease 0.69 (0.62 to 0.77) 0.78 (0.69 to 0.87)
Concurrent organ disorder
(chronic comorbidities) C
Hypertension 0.74 (0.65 to 0.83) 0.82 (0.73 to 0.93)
COPD 0.81 (0.73 to 0.91) 0.88 (0.79 to 0.98)
Hospital level
District 1.00 1.00
Regional 1.12 (1.02 to 1.23) 1.02 (0.93 to 1.12)
Medical center 1.00 (0.91 to 1.09) 0.91 (0.83 to 1.00)
aCI, confidence interval; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal. bHazard ratio adjusted for cancer type, gender, age, extent of cancer,
acute and chronic comorbidities, and hospital level. cThe reference group is without the comorbidity listed below.
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of those with cancer of the head, neck, esophagus, skin or
nervous system. Half of those patients under PMV sur-
vived less than 1.4 months with an overall 1-yr survival
rate of 14.3% (95% CI, 13.3% to 15.3%), which is generally
poorer than that of patients with other comorbidities [13].
Among different types of cancer, those occurring in the
lung and nervous system seemed to have the highest inci-
dence of ICU admissions (Table 2). This might be asso-
ciated with direct tumor involvement of the respiratory
tract and/or the control of ventilation. Patients with liver
cancer were found to exhibit the lowest incidence of
PMV, which may be related to their lower survival rate
and life expectancy (Table 1).
Previous studies of cancer patients requiring ventilator
support in the ICU could differentiate cancer types into
only solid and hematological malignancy because of small
numbers [7,26,27]. Among them, Soares et al. reported a
60% rate of 6-month mortality for 163 patients who had a
prolonged ICU length of stay (21 days or longer), and the
number of organ failures, old age and poor performance
status were significantly associated with poor outcomes
[27]. Nonetheless, in our study, with 10-yr follow-up of a
nationwide collection of cases, we have been able to detect
cancer occurring in different organ systems as a predictor
of lifetime mortality after adjustment for multiple con-
founders (Table 3). It is also noteworthy that age is not
related to the outcomes in our study, which might indicate
that cancer patients under PMV are usually at the most
severe stage, with a life expectancy of 1.21 yr. Thus, age
did not appear to influence such an overall poor prognosis.
Critical care with mechanical ventilation has been
advocated as a therapeutic trial for critically ill cancer
patients, but failure of such care might signal a need for a
transition from curative to palliative care [28,29]. Patients
and their families may be more likely to accept revision
of the goal of care when there is little hope for meaning-
ful recovery [30]. In many occasions, however, stake-
holders have too little important prognostic information,
especially with regard to reliable estimates of life expec-
tancies for different conditions, to use in making deci-
sions [31]. The long-term outcomes and prognostic
factors for PMV cancer patients in our study may thus be
useful for communication among all stakeholders to
facilitate patient-centered clinical decisions and possible
early integration of palliative care, which is very crucial in
Taiwan, where regulations for extubation are rather
restrictive. This used to require the signatures of all first-
degree relatives; but, in 2013, the rule was changed to
require only one signature.
In addition to survival, a more ideal outcome evaluation
must also take QoL into consideration. Assuming that the
QoL of these patients is similar to that of other PMV
patients, we tried to categorize them into patients with
poor cognition and those with partial cognitive ability.
Using that method, the overall QALE would be about 0.17
to 0.37 QALY. Even for patients with colorectal cancer
requiring PMV who had the longest survival, the QALE
was only 0.20 to 0.45 QALYs for patients with poor cogni-
tion and those with partial cognitive ability, respectively.
Further evaluation of the cost per QALY in another study
for patients under PMV found that cancer patients spent
$64,708 and US$148,829 per QALY with partial versus
poor cognition, respectively. Both figures cost more than
three times Taiwan’s gross domestic product and were not
considered cost-effective based on criteria suggested by
the World Health Organization’s CHOosing Interventions
that are Cost-Effective (WHO-CHOICE) guideline [32].
The out-of-pocket expenses were estimated to be about
one-third those including such spending [14]. Thus, we
recommend that palliative care be considered early, espe-
cially among patients with metastasis, to avoid a prolonged
dying process.
Our study has the following limitations. First, the data-
base did not contain any information regarding the para-
meters of prior performance status, which has been
reported to be predictive for long-term survival in criti-
cally ill cancer patients, including those requiring
mechanical ventilation [9,33,34]. As poor performance
status was usually associated with advanced or metastatic
cancer [35], the HR we obtained in this study might be
overestimated. Second, because the billing records in the
NHIRD provide neither the exact date of tracheostomy
nor the main reasons for ICU admission, we were unable
to stratify these patients by the stability of their clinical
course. Further prospective study is warranted to clarify
this issue. Third, decisions to limit therapy, and particu-
larly “do not resuscitate” (DNR) orders, were not
recorded in the NHI data. Patients with DNR orders may
prevent the use of aggressive treatment, which may be a
crucial confounding factor in the survival analysis.
Although we recommend that future studies take this
factor into account, the magnitude of potential bias
resulting from this factor might be quite limited in our
present study because all cancer patients under PMV
were already intubated, and, because of the legal restric-
tions in Taiwan before 2011, no one, even with the con-
sent of all family members, was allowed to withdraw
PMV. Thus, considerations for these patients were pre-
sumed to be those without DNR consent. However, the
adaptation of PMV incidence in our study should be cau-
tious because life-supporting treatment would be allowed
to be withdrawn in other countries under certain circum-
stances [36,37].
Conclusions
Cancer patients undergoing mechanical ventilation for more
than 7 days usually had a poor long-term outcome, espe-
cially those under PMV, which we defined as continuous
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mechanical ventilation for more than 21 days. In our opi-
nion, palliative care should be considered early in cancer
patients with metastases. The extent of treatment and
end-of-life issues should be openly discussed in the early
stages of care for cancer patients. In Taiwan, too often this
discussion begins after a patient’s loss of decision-making
ability, suggesting general ignorance of the principle of
respect for autonomy. Our results also call to attention the
cost-effectiveness of current policies in the care of cancer
patients undergoing PMV.
Key messages
• Half of cancer patients under PMV survived less
than 1.4 months, and the overall 1-yr survival rate was
14.3%.
• Cancer of the liver and lung and metastasis indepen-
dently predict shorter survival.
• We recommend that palliative care be considered
early in mechanically ventilated patients with meta-
static cancer.
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